NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Lifshitz Law PLLC:
Treace Medical Concepts, Inc. (NASDAQ:TMCI)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. Specifically, the Company allegedly failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System; (2) as a result, Treace Medical’s revenue declined, and the Company needed to accelerate its plans to offer a product that served as an alternative to osteotomy (a surgical procedure involving the cutting and realignment of a bone to improve its position or function); and (3) the Company’s positive statements about the its business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you are a TMCI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Zenas BioPharma, Inc. (NASDAQ:ZBIO)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. On August 22, 2024, Zenas BioPharma filed with the SEC a Registration Statement on Form S-1, which in combination with a subsequent amendment on Form S-1/A, and which was declared effective by the SEC on September 12, 2024, would be used for the IPO. In the IPO, Zenas BioPharma sold 13,235,294 shares at $17.00 per share. Specifically, the registration statement allegedly contained false and/or misleading statements and/or failed to disclose that: 1) Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, the Company’s public statements were materially false and misleading.
If you are a ZBIO investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Ibotta, Inc. (NYSE:IBTA)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. Allegedly, statements made in the Registration Statement issued in connection with Ibotta’s April 18, 2024, initial public offering were false and/or misleading when made because they did not properly warn investors of the risks concerning Ibotta’s contract with The Kroger Co. Kroger’s contract was at-will, and Ibotta failed to warn investors that a large client could cancel their contract with Ibotta without warning. Despite providing a detailed explanation of the terms of Ibotta’s contract with Walmart, there was not a single warning of the at-will nature of Kroger’s contract.
If you are an IBTA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Avis Budget Group, Inc. (NYSE:CAR)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. Specifically, the Company allegedly made false and/or misleading statements and/or failed to disclose that: (1) Avis Budget crafted and implemented a plan to significantly accelerate its fleet rotation in the fourth quarter of 2024; (2) the foregoing acceleration shortened the useful life of the majority of the Company’s vehicles in the Americas segment, thereby reducing their recoverable value; (3) as a result, Avis Budget would be forced to recognize billions of dollars in impairment charges and incur substantial losses; (4) all the foregoing was likely to, and did, have a significant negative impact on the Company’s financial results; (5) accordingly, Avis Budget’s financial and/or business prospects were overstated; and (6) as a result, the Company’s public statements were materially false and misleading.
If you are a CAR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
ATTORNEY ADVERTISING.© 2025 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: jlifshitz@lifshitzlaw.com
SOURCE:
View the original press release on ACCESS Newswire
COMTEX_468236469/2457/2025-08-22T14:48:03